Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma

AT did not improve survival, however was more commonly administered in advanced disease. Stage I patients had high recurrence rates but rarely received AT. Prospective evaluation of appropriate AT regimens and use in early stage patients should be considered.